

=> fil reg; d ide 1-6

FILE 'REGISTRY' ENTERED AT 14:49:36 ON 12 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2003 HIGHEST RN 625827-33-0
DICTIONARY FILE UPDATES: 11 DEC 2003 HIGHEST RN 625827-33-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L16 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN 308068-55-5, REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may
result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN Mucopolysaccharides, heparinoids (CA INDEX NAME)

OTHER NAMES:

CN Danaparoid

CN Heparinoids

CN Lomoparan

CN OH 10172

CN Orgaran

MF Unspecified

CI MAN, CTS

SR CA

LC STN Files: IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L16 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN 114870-03-0, REGISTRY

CN .alpha.-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-
.alpha.-D-glucopyranosyl-(1.fwdarw.4)-O-.beta.-D-glucopyranuronosyl-
(1.fwdarw.4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-.alpha.-D-
glucopyranosyl-(1.fwdarw.4)-O-2-O-sulfo-.alpha.-L-idopyranuronosyl-
(1.fwdarw.4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium
salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Arixtra

CN Fondaparinux sodium

CN Fondaparinux sodium

CN IC 85158

CN IC 851589

CN Org 31540

CN SR 90107A

CN Xantidar

FS STEREOSEARCH

DR 350014-67-4

MF C31 H53 N3 O49 S8 . 10 Na

SR CA


LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DIOGENES, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

CRN (104993-28-4)


Absolute stereochemistry.

PAGE 1-A



● 10 Na

PAGE 1-B



80 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

81 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN (104993-28-4) REGISTRY

CN .alpha.-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-.alpha.-D-glucopyranosyl-(1.fwdarw.4)-O-.beta.-D-glucopyranuronosyl-(1.fwdarw.4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-.alpha.-D-glucopyranosyl-(1.fwdarw.4)-O-2-O-sulfo-.alpha.-L-idopyranuronosyl-(1.fwdarw.4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Fondaparinux

CN PENTA

CN **SR 90107**

FS STEREOSEARCH

DR 129051-67-8, 119329-39-4, 147827-38-1, 214767-51-8, 389064-08-8,
393796-46-8, 393796-99-1, 412015-07-7

MF C31 H53 N3 O49 S8


CI COM

SR CA


LC STN Files: BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS,
EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PIRA,
PROMT, SYNTHLINE, TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

80 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

80 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN 37270-89-6 REGISTRY

CN Heparin, calcium salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Calciparin

CN Calciparine
CN Calcium heparin
CN Calcium heparinate
CN Ecasolv
CN Hepacarin
CN Heparin calcium
CN Nadroparin calcium
DR 101921-20-4, 39363-70-7
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CANCERLIT, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,
DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PROMT, RTECS*, TOXCENTER,
USPATFULL, VETU
(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

155 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

155 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN 9041-08-1 REGISTRY

CN Heparin, sodium salt (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN Alfa 87-120
CN Alfa 87-163
CN Alfa 87-198
CN Alfa 87-81
CN Alfa 88-247
CN Ardeparin sodium
CN Bemiparin sodium
CN Clexan
CN Dalteparin sodium
CN Deligoparin sodium
CN Depo-Heparin
CN Enoxaparin sodium
CN Fragmin
CN Fragmin IV
CN H 2149
CN Hed-Heparin
CN Hepalean
CN Heparin Fragment Kabi 2165
CN Heparin sodium
CN Hepathrom
CN Heprinar
CN Hepsal
CN Inno-Hep
CN Kabi 2165
CN LHN 1
CN Lioton 1000
CN Lipo-Hepin
CN Lipo-Hepinette
CN Liquaemin sodium
CN Liquemin
CN Logiparin
CN Longheparin
CN Lovenox
CN Minihep
CN Minolteparin sodium
CN Monoparin
CN Normiflo

CN OP 2000
CN Panheprin
CN Parnaparin sodium
CN PK 10169
CN Pularin
CN Reviparin sodium
CN RO 11
CN RP 54563
CN Sodium acid heparin
CN Sodium heparin
CN Sodium heparinate
CN Sodium parnaparin
CN Thrombo-Hepin
CN Tinzaparin sodium

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

DR 12656-11-0, 101921-26-0, 102785-31-9

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration, Polyester, Polyester formed

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN,
CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,
IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
MSDS-OHS, NIOSHTIC, PHAR, PROMT, RTECS*, TOXCENTER, USAN, USPAT2,
USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1111 REFERENCES IN FILE CA (1907 TO DATE)

86 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1114 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2003 ACS on STN

RN 9005-49-6 REGISTRY

CN Heparin (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN .alpha.-Heparin

CN Arteven

CN Bemiparin

CN Certoparin

CN Clevarin

CN Clexane

CN Clivarin

CN Clivarine

CN CY 216

CN CY 222

CN Dalteparin

CN Enoxaparin

CN Fluxum

CN FR 860

CN Fragmin A

CN Fragmin B

CN Fraxiparin

CN Heparin subcutan

CN Heparin sulfate

CN Heparinic acid

CN KB 101

CN Leparan

CN Mono-embolox

CN Multiparin

CN **Nadroparin**
CN Novoheparin
CN OP 386
CN OP 622
CN Pabyrn
CN **Parnaparin**
CN Parvoparin
CN **Reviparin**
CN Sandoparin
CN Sublingula
CN **Tinzaparin**
CN Vetren
CN Vitrum AB
DR 9075-96-1, 11078-24-3, 11129-39-8, 104521-37-1, 37324-73-5, 91449-79-5
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration, Polyester, Polyester formed
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST,
CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT,
IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,
MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

22491 REFERENCES IN FILE CA (1907 TO DATE)

1806 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

22518 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil capl; d que 135

FILE 'CAPLUS' ENTERED AT 15:15:00 ON 12 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2003 VOL 139 ISS 25

FILE LAST UPDATED: 11 Dec 2003 (20031211/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L4 2 SEA FILE=REGISTRY ABB=ON ENOXAPARIN#/CN
L5 2 SEA FILE=REGISTRY ABB=ON NADROPARIN#/CN
L6 2 SEA FILE=REGISTRY ABB=ON PARNAPARIN#/CN
L7 2 SEA FILE=REGISTRY ABB=ON REVIPARIN#/CN
L8 2 SEA FILE=REGISTRY ABB=ON DALTEPARIN#/CN
L9 2 SEA FILE=REGISTRY ABB=ON TINZAPARIN#/CN
L10 1 SEA FILE=REGISTRY ABB=ON DANAPAROID/CN
L11 1 SEA FILE=REGISTRY ABB=ON ARDEPARIN#/CN
L12 1 SEA FILE=REGISTRY ABB=ON CERTOPARIN/CN
L13 1 SEA FILE=REGISTRY ABB=ON "CY 222"/CN
L14 1 SEA FILE=REGISTRY ABB=ON "SR 90107"/CN
L15 1 SEA FILE=REGISTRY ABB=ON "ORG 31540"/CN
L16 6 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15)
L17 23396 SEA FILE=CAPLUS ABB=ON L16
L18 1 SEA FILE=REGISTRY ABB=ON HEPARIN/CN
L19 76 SEA FILE=CAPLUS ABB=ON L18/D(L)LOW
L20 3808 SEA FILE=CAPLUS ABB=ON LATERAL SCLEROSIS
L21 892 SEA FILE=CAPLUS ABB=ON (SPINAL OR PROGRESSIVE OR INFANTILE) (1W) MUSCULAR ATROPH?
L22 2 SEA FILE=CAPLUS ABB=ON (BULBO SPINAL OR BULBOSPINAL) (W) (NEUROPATH? OR ATROPH?)
L23 0 SEA FILE=CAPLUS ABB=ON MYELOPATHIC MUSCULAR ATROPH?
L24 26 SEA FILE=CAPLUS ABB=ON KUGELBERG(A)WELANDER OR WERDNIG(A)HOFFMAN
L25 690 SEA FILE=CAPLUS ABB=ON MOTOR(W) (SYSTEM OR NEURON) (2A)DISEASE#
L26 30 SEA FILE=CAPLUS ABB=ON BULBAR(W) (PALSY OR PARALYSIS)
L34 977 SEA FILE=CAPLUS ABB=ON ENOXAPARIN# OR NADROPARIN# OR PARNAPARIN# OR REVIPARIN# OR DALTEPARIN# OR TINZAPARIN# OR DANAPAROID# OR ARDEPARIN# OR CERTOPARIN# OR CY 222 OR SR 90107 OR ORG 31540
L35 14 SEA FILE=CAPLUS ABB=ON (L17 OR L19 OR L34) AND (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26)

=> fil medl; d que 13

FILE 'MEDLINE' ENTERED AT 15:15:01 ON 12 DEC 2003

FILE LAST UPDATED: 2 DEC 2003 (20031202/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 4315 SEA FILE=MEDLINE ABB=ON HEPARIN, LOW-MOLECULAR-WEIGHT+NT/CT

L2 15424 SEA FILE=MEDLINE ABB=ON MOTOR NEURON DISEASE+NT/CT

L3 0 SEA FILE=MEDLINE ABB=ON L1 AND L2

*- this term includes
the specific diseases
of claim 3*

=> fil uspatf; d que 159

FILE 'USPATFULL' ENTERED AT 15:15:02 ON 12 DEC 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 11 Dec 2003 (20031211/PD)

FILE LAST UPDATED: 11 Dec 2003 (20031211/ED)

HIGHEST GRANTED PATENT NUMBER: US6662368

HIGHEST APPLICATION PUBLICATION NUMBER: US2003229929

CA INDEXING IS CURRENT THROUGH 11 Dec 2003 (20031211/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 11 Dec 2003 (20031211/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2003

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L4 2 SEA FILE=REGISTRY ABB=ON ENOXAPARIN?/CN

L5 2 SEA FILE=REGISTRY ABB=ON NADROPARIN?/CN

L6 2 SEA FILE=REGISTRY ABB=ON PARNAPARIN?/CN

L7 2 SEA FILE=REGISTRY ABB=ON REVIPARIN?/CN

L8 2 SEA FILE=REGISTRY ABB=ON DALTEPARIN?/CN

L9 2 SEA FILE=REGISTRY ABB=ON TINZAPARIN?/CN
L10 1 SEA FILE=REGISTRY ABB=ON DANAPAROID/CN
L11 1 SEA FILE=REGISTRY ABB=ON ARDEPARIN?/CN
L12 1 SEA FILE=REGISTRY ABB=ON CERTOPARIN/CN
L13 1 SEA FILE=REGISTRY ABB=ON "CY 222"/CN
L14 1 SEA FILE=REGISTRY ABB=ON "SR 90107"/CN
L15 1 SEA FILE=REGISTRY ABB=ON "ORG 31540"/CN
L16 6 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR
L10 OR L11 OR L12 OR L13 OR L14 OR L15)
L49 2233 SEA FILE=USPATFULL ABB=ON L16 OR (ENOXAPARIN# OR NADROPARIN#
OR PARNAPARIN# OR REVIPARIN#)/IT, TI, AB, CLM
L50 26 SEA FILE=USPATFULL ABB=ON (DALTEPARIN# OR TINZAPARIN# OR
DANAPAROID# OR ARDEPARIN# OR CERTOPARIN#)/IT, TI, AB, CLM
L51 5 SEA FILE=USPATFULL ABB=ON (CY 222 OR SR 90107 OR ORG 31540 OR
CALCIPARIN# OR HEPACARIN#)/IT, TI, AB, CLM
L52 253 SEA FILE=USPATFULL ABB=ON (HEPARIN(3A)LOW)/IT, TI, AB, CLM
L53 1269 SEA FILE=USPATFULL ABB=ON (LATERAL SCLEROSIS)/IT, TI, AB, CLM
L54 133 SEA FILE=USPATFULL ABB=ON ((SPINAL OR PROGRESSIVE OR INFANTILE
OR MYELOPATHIC) (1W) MUSCULAR ATROPH?)/IT, TI, AB, CLM
L55 0 SEA FILE=USPATFULL ABB=ON ((BULBO SPINAL OR BULBOSPINAL) (W) (NE
UROPATH? OR ATROPH?))/IT, TI, AB, CLM
L56 6 SEA FILE=USPATFULL ABB=ON (KUGELBERG(A) WELANDER OR WERDNIG(A) H
OFFMAN)/IT, TI, AB, CLM
L57 104 SEA FILE=USPATFULL ABB=ON (MOTOR(W) (SYSTEM OR NEURON) (2A) DISEA
SE#)/IT, TI, AB, CLM
L58 8 SEA FILE=USPATFULL ABB=ON (BULBAR(W) (PALSY OR PARALYSIS))/IT, T
I, AB, CLM
L59 13 SEA FILE=USPATFULL ABB=ON (L49 OR L50 OR L51 OR L52) AND (L53
OR L54 OR L55 OR L56 OR L57 OR L58)

=> fil embase; d que 164

FILE 'EMBASE' ENTERED AT 15:15:03 ON 12 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 11 Dec 2003 (20031211/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L4 2 SEA FILE=REGISTRY ABB=ON ENOXAPARIN?/CN
L5 2 SEA FILE=REGISTRY ABB=ON NADROPARIN?/CN
L6 2 SEA FILE=REGISTRY ABB=ON PARNAPARIN?/CN
L7 2 SEA FILE=REGISTRY ABB=ON REVIPARIN?/CN
L8 2 SEA FILE=REGISTRY ABB=ON DALTEPARIN?/CN
L9 2 SEA FILE=REGISTRY ABB=ON TINZAPARIN?/CN
L10 1 SEA FILE=REGISTRY ABB=ON DANAPAROID/CN
L11 1 SEA FILE=REGISTRY ABB=ON ARDEPARIN?/CN
L12 1 SEA FILE=REGISTRY ABB=ON CERTOPARIN/CN
L13 1 SEA FILE=REGISTRY ABB=ON "CY 222"/CN
L14 1 SEA FILE=REGISTRY ABB=ON "SR 90107"/CN
L15 1 SEA FILE=REGISTRY ABB=ON "ORG 31540"/CN
L16 6 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR
L10 OR L11 OR L12 OR L13 OR L14 OR L15)
L60 5445 SEA FILE=EMBASE ABB=ON L16
L61 10267 SEA FILE=EMBASE ABB=ON LOW MOLECULAR WEIGHT HEPARIN+NT/CT
L62 9640 SEA FILE=EMBASE ABB=ON SPINAL MUSCULAR ATROPHY+NT/CT
L63 286 SEA FILE=EMBASE ABB=ON WERDNIG HOFFMANN DISEASE/CT
L64 5 SEA FILE=EMBASE ABB=ON (L60 OR L61) AND (L62 OR L63)

=> fil PASCAL, JICST-EPLUS, ESBIODASE, BIOTECHDS, LIFESCI, CONFSCI, WPIDS; d que 175

FILE 'PASCAL' ENTERED AT 15:15:03 ON 12 DEC 2003

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'ESBIODASE' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'LIFESCI' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CONFSCI' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:15:03 ON 12 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

L65 1190 SEA ENOXAPARIN# OR NADROPARIN# OR PARNAPARIN# OR REVIPARIN#
L66 799 SEA ABB=ON DALTEPARIN# OR TINZAPARIN# OR DANAPAROID# OR
ARDEPARIN# OR CERTOPARIN#
L67 152 SEA ABB=ON CY 222 OR SR 90107 OR ORG 31540 OR CALCIPARIN# OR
HEPACARIN#
L68 5189 SEA ABB=ON HEPARIN(3A) LOW
L69 11801 SEA ABB=ON LATERAL SCLEROSIS
L70 2215 SEA ABB=ON (SPINAL OR PROGRESSIVE OR INFANTILE OR MYELOPATHIC)
(1W) MUSCULAR ATROPH?
L71 9 SEA ABB=ON (BULBO SPINAL OR BULBOSPINAL) (W) (NEUROPATH? OR
ATROPH?)
L72 260 SEA ABB=ON KUGELBERG(A) WELANDER OR WERDNIG(A) HOFFMAN
L73 3386 SEA ABB=ON MOTOR(W) (SYSTEM OR NEURON) (2A) DISEASE#
L74 367 SEA ABB=ON BULBAR(W) (PALSY OR PARALYSIS)
L75 1 SEA (L65 OR L66 OR L67 OR L68) AND (L69 OR L70 OR L71 OR L72
(OR L73 OR L74)

=> fil DRUGU, BIOTECHNO, CABA, IPA, BIOSIS, TOXCENTER; d que 148

FILE 'DRUGU' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOTECHNO' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'IPA' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'BIOSIS' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 15:15:04 ON 12 DEC 2003

COPYRIGHT (C) 2003 ACS

L4 2 SEA FILE=REGISTRY ABB=ON ENOXAPARIN?/CN
L5 2 SEA FILE=REGISTRY ABB=ON NADROPARIN?/CN
L6 2 SEA FILE=REGISTRY ABB=ON PARNAPARIN?/CN
L7 2 SEA FILE=REGISTRY ABB=ON REVIPARIN?/CN
L8 2 SEA FILE=REGISTRY ABB=ON DALTEPARIN?/CN
L9 2 SEA FILE=REGISTRY ABB=ON TINZAPARIN?/CN
L10 1 SEA FILE=REGISTRY ABB=ON DANAPAROID/CN
L11 1 SEA FILE=REGISTRY ABB=ON ARDEPARIN?/CN
L12 1 SEA FILE=REGISTRY ABB=ON CERTOPARIN/CN
L13 1 SEA FILE=REGISTRY ABB=ON "CY 222"/CN
L14 1 SEA FILE=REGISTRY ABB=ON "SR 90107"/CN
L15 1 SEA FILE=REGISTRY ABB=ON "ORG 31540"/CN
L16 6 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR
L10 OR L11 OR L12 OR L13 OR L14 OR L15)
L38 61653 SEA L16 OR ENOXAPARIN# OR NADROPARIN# OR PARNAPARIN# OR
REVIPARIN#
L39 3469 SEA DALTEPARIN# OR TINZAPARIN# OR DANAPAROID# OR ARDEPARIN# OR
CERTOPARIN#
L40 742 SEA CY 222 OR SR 90107 OR ORG 31540 OR CALCIPARIN# OR HEPACARIN

L41 14458 SEA HEPARIN(3A) LOW
L42 11428 SEA LATERAL SCLEROSIS
L43 3072 SEA ABB=ON (SPINAL OR PROGRESSIVE OR INFANTILE OR MYELOPATHIC)
(1W) MUSCULAR ATROPH?
L44 9 SEA ABB=ON (BULBO SPINAL OR BULBOSPINAL) (W) (NEUROPATH? OR
ATROPH?)
L45 260 SEA ABB=ON KUGELBERG(A) WELANDER OR WERDNIG(A) HOFFMAN
L46 4122 SEA ABB=ON MOTOR(W) (SYSTEM OR NEURON) (2A) DISEASE#
L47 384 SEA ABB=ON BULBAR(W) (PALSY OR PARALYSIS)
L48 3 SEA (L38 OR L39 OR L40 OR L41) AND (L42 OR L43 OR L44 OR L45)
OR L46 OR L47)

=> dup rem 135,159,148,164,175

FILE 'CAPLUS' ENTERED AT 15:15:06 ON 12 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:15:06 ON 12 DEC 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 15:15:06 ON 12 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 15:15:06 ON 12 DEC 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:15:06 ON 12 DEC 2003

COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:15:06 ON 12 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

PROCESSING COMPLETED FOR L35

PROCESSING COMPLETED FOR L59

PROCESSING COMPLETED FOR L48

PROCESSING COMPLETED FOR L64

PROCESSING COMPLETED FOR L75

L76 35 DUP REM L35 L59 L48 L64 L75 (1 DUPLICATE REMOVED)

ANSWERS '1-14' FROM FILE CAPLUS

ANSWERS '15-27' FROM FILE USPATFULL

ANSWERS '28-29' FROM FILE BIOSIS

ANSWERS '30-34' FROM FILE EMBASE

ANSWER '35' FROM FILE WPIDS

=> d ibib ab hitrn 1-27; d iall 28-35; fil hom

L76 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2002:283439 CAPLUS

DOCUMENT NUMBER: 137:936

TITLE: Co-administration of IGF-I and glycosaminoglycans greatly delays **motor neuron disease** and affects IGF-I expression in the wobbler mouse: A long-term study

AUTHOR(S): Gorio, Alfredo; Lesma, Elena; Madaschi, Laura; Di Giulio, Anna Maria

CORPORATE SOURCE: Pharmacological Laboratories, Departments of Medicine, Surgery and Odontoiatry, Polo H San Paolo, Faculty of Medicine, Milan, 20142, Italy

SOURCE: Journal of Neurochemistry (2002), 81(1), 194-202
CODEN: JONRA9; ISSN: 0022-3042

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The study on wobbler mouse has shown that the combined treatment with low doses of glycosaminoglycans (GAGs) and IGF-I fully prevented motor neuron death and forelimb impairment up to 9-12 wk of a mouse's life. The effect was accompanied by the prevention of the early hypertrophy of wobbler neurons, an effect likely due to the promotion of neuronal survival. At the 18th week, wobbler mice treated with IGF-I + GAGs still showed significantly improved forelimb function, reduced muscle atrophy and a higher no. of cervical motor neurons. IGF-I alone and GAGs alone were active up to the 3rd week of treatment; thereafter the beneficial effects of single treatments decreased drastically. GAGs and IGF-I treatments also affected IGF-I plasma and muscle levels. In wobbler mice there was a progressive redn. in IGF-I plasma levels that was prevented by IGF-I or GAGs alone and greatly increased, even above heterozygote levels, by the combination treatment. Such a powerful increase was correlated by a small enhancement in IGFBP-3 plasma levels, while treatment with IGF-I alone affected very significantly both IGFBP-1 and IGFBP-3. Co-treatment also prevented the decrease in IGF-I content obsd. in vehicle-treated wobbler mice forelimb muscles.

IT 9005-49-6, Heparin sulfate, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined with dermatan sulfate; IGF-I and glycosaminoglycan coadministration delays **motor neuron disease** and affects IGF-I expression in wobbler mouse)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:397015 CAPLUS

DOCUMENT NUMBER: 138:397896

TITLE: Secreted Frizzled-related protein 1 inducing differentiation of embryonic stem cells into ectodermal cells and its use

INVENTOR(S): Sasai, Yoshiki; Iwata, Hiroo; Murakami, Yoshinobu; Satoh, Mitsuo; Kobori, Masato; Yano, Keiichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042384	A1	20030522	WO 2002-JP11894	20021114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2001-350724 A 20011115

AB A method of obtaining a soln. having an activity of inducing the differentiation of embryo stem cells into ectodermal cells or ectoderm-origin cells; and factors obtained by such method for inducing the differentiation of embryo stem cells into ectodermal cells or ectoderm-origin cells; are disclosed. The method involves the step of culturing stroma cells on a liq. medium contg. a polyanion compd. , neg. charged copolymer or homopolymer and then recovering the liq. medium. Also provided are: stroma cells or a factor derived from stroma cells possessing an activity to induce the differentiation in this method; cells induced by this method; and a method for increasing the purity of cells obtained by culturing in the presence of anticancer agents. A method is also provided for evaluating/screening a substance related to the regulation of the differentiation process from embryonic stem cells to ectodermal cells or cells derived from ectoderm by performing this method. Also provided are the pharmaceuticals contg. the above-described stroma cells or the factor derived from the stroma cells, or the above-described cells. The authors identified a stromal cell-derived inducing activity (SDIA), which induces differentiation of neural cells, including midbrain tyrosine hydroxylase-pos. (TH+) dopaminergic neurons, from mouse embryonic stem cells. The authors report here that SDIA is Secreted Frizzled-related protein 1 (SFRP1), a member of a protein family that contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors and regulates the WNT pathway and induces efficient neural differentiation in embryonic stem cells.

IT 9005-49-6, Heparin, biological studies

RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)

(culturing stroma cells on a liq. medium contg.; Secreted

Frizzled-related protein 1 inducing differentiation of embryonic stem cells into ectodermal cells and its use)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:117964 CAPLUS

DOCUMENT NUMBER: 138:165523

TITLE: Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans and therapeutic uses thereof

INVENTOR(S): Loeb, Jeffrey A.

PATENT ASSIGNEE(S): Wayne State University, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003012045	A2	20030213	WO 2002-US24053	20020731
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-308563P P 20010731

AB The present invention discloses that the neuregulin (NRG) heparin binding domain (N-HBD) functions to keep the EGF-like domain at sufficiently high concns. near erbB receptors for a sufficiently long period of time necessary to induce events downstream from receptor binding. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homolog or functional deriv. and a protein to be targeted. This is fused to a polypeptide or peptide being targeted (Ptrg) to cell surfaces rich in heparan sulfate proteoglycans to either activate or inhibit interactions at tyrosine kinase receptors. Such products are used to treat diseases or conditions where either agonism or antagonism at tyrosine kinase receptors has beneficial effects, including cancer and a multitude of diseases of the nervous system. The present inventor examd. how NRG-HSPG interactions affect NRG-erbB receptor binding, erbB receptor auto-phosphorylation and downstream activation of AChR genes and newly-synthesized proteins in primary chick myotube cultures.

IT 9005-49-6, Heparin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans and therapeutic uses thereof)

L76 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:76905 CAPLUS

DOCUMENT NUMBER: 138:133498

TITLE: Production of radial glial cells from neural stem cells and ependymal cells in the presence of growth factors and therapeutic applications

INVENTOR(S): Weiss, Samuel; Gregg, Christopher

PATENT ASSIGNEE(S): Stem Cell Therapeutics Inc., Can.

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008566	A1	20030130	WO 2002-CA1087	20020719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

US 2003032181 A1 20030213 US 2002-196549 20020717

PRIORITY APPLN. INFO.: US 2001-307096P P 20010720

CA 2001-2364095 A 20011130

AB The present invention relates to a method of producing radial glial cells from neural stem cells, particularly by contacting neural stem cells with epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2) and/or TGF.alpha.. Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can optionally be added to enhance the effect of EGF, FGF-2 or TGF.alpha.. Also provided are methods of producing radial glial cells from ependymal cells, as well as methods of proliferating ependymal cells. A method for treating a CNS disease in a mammal by transplanting radial glial cells into the mammal is disclosed. A method for enhancing neural cell mobilization in a mammal by administering a radial glia promoting agent of transplanting radial glial cells into the mammal is also provided.

IT 9005-49-6, Heparin sulfate, biological studies

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(glial cells prodn. in presence of growth factors and; prodn. of radial glial cells from neural stem cells and ependymal cells in presence of growth factors and therapeutic applications)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:6095 CAPLUS

DOCUMENT NUMBER: 138:52352

TITLE: Method of producing region-specific neurons from human neuronal stem cells

INVENTOR(S): Wu, Ping F.

PATENT ASSIGNEE(S): The University of Texas System, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000852	A2	20030103	WO 2002-US19743	20020619
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003013193 A1 20030116 US 2002-176971 20020619

PRIORITY APPLN. INFO.: US 2001-300344P P 20010622

AB The invention concerns a method of priming neural stem cells in vitro by

adhesively culturing in a mixt. of basic fibroblast growth factor, laminin and heparin to differentiate into specific neuronal phenotypes, including cholinergic, glutamatergic and GABAergic neurons, in a region-specific manner, when transplanted in vivo.

IT 9005-49-6, Heparin, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(method of producing region-specific neurons from human neuronal stem cells)

L76 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:588647 CAPLUS

DOCUMENT NUMBER: 139:112759

TITLE: Protein and cDNA sequences of a human glial-derived neurotrophic factor and therapeutic use for nervous system diseases

INVENTOR(S): Zhou, Shoushan; Zheng, Zanshun; Fang, Haizhou; Chen, Yong; Jiang, Ruofeng; Zhu, Aitang; Zhang, Qi; Gan, Shuyan; Lan, Xuan

PATENT ASSIGNEE(S): Zhuhai Yisheng Biopharmaceuticals Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 28 pp. CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1364812	A	20020821	CN 2001-107450	20010111
PRIORITY APPLN. INFO.:			CN 2001-107450	20010111

AB The invention provides the DNA sequence or its DNA fragments and their encoded amino acid sequences of human glial-derived neurotrophic factor (GDNF) cloned from human glioma cell line C6 or synthesized by solid-phase synthesis method. The invention relates to the construction of the expression vector, the expression of GDNF in E.coli, yeast, and CHO cells, and sepn. and purifn. of GDNF from the cultured products of the above genetically engineered bacteria or CHO cells. The invention also relates to the application of the expressed GDNF in prepg. the medical compn. (composed of GDNF, natural ganglioside or its deriv., and/or mycose or hyaluronic acid) for treating nervous system disease, insanity, etc.

IT 9005-49-6, Heparin, uses

RL: DEV (Device component use); USES (Uses)

(protein and cDNA sequences of human glial-derived neurotrophic factor and therapeutic use for nervous system diseases)

L76 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:851346 CAPLUS

DOCUMENT NUMBER: 135:368940

TITLE: Novel method for inducing the differentiation of embryonic stem cells into ectodermal cells and its use

INVENTOR(S): Sasai, Yoshiki; Nishikawa, Shinichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001088100 A1 20011122 WO 2001-JP4080 20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001056767 A5 20011126 AU 2001-56767 20010516
US 2002151056 A1 20021017 US 2001-855587 20010516
EP 1302533 A1 20030416 EP 2001-930185 20010516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: JP 2000-144059 A 20000516
JP 2000-290819 A 20000925
US 2000-257049P P 20001220
WO 2001-JP4080 W 20010516

AB A novel method for inducing the differentiation of embryonic stem cells into ectodermal cells or cells derived from ectoderm is provided, in which a process for culturing embryonic stem cells in a non-aggregated state is included. Also provided are: culture medium and culture supernatant used for this method; a differentiation inducer used in this method; stroma cells or a factor derived from stroma cells possessing an activity to induce the differentiation in this method; an antibody capable of specifically recognizing the stroma cells; an antigen capable of recognizing the antibody; and cells induced by this method. A method is also provided for evaluating/screening a substance related to the regulation of the differentiation process from embryonic stem cells to ectodermal cells or cells derived from ectoderm by performing this method. Also provided are the pharmaceuticals contg. the above-described stroma cells or the factor derived from the stroma cells, the above-described antibody, the above-described antigen, or the above-described cells.

IT 9005-49-6, Heparin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(novel method for inducing differentiation of embryonic stem cells into ectodermal cells and use)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:824499 CAPLUS

DOCUMENT NUMBER: 134:14946

TITLE: A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses in diagnosis and maintaining synaptic connections

INVENTOR(S): Role, Lorna W.; Talmage, David; Bao, Jianxin.

PATENT ASSIGNEE(S): The Trustees of Columbia University In the City of New York, USA

SOURCE: PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000070322	A2	20001123	WO 2000-US13157	20000512
WO 2000070322	A3	20011011		
WO 2000070322	C2	20020926		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000048474 A5 20001205 AU 2000-48474 20000512
PRIORITY APPLN. INFO.: US 1999-312596 A 19990514
WO 2000-US13157 W 20000512

AB This invention provides an assay for diagnosing whether a subject has or is predisposed to developing a neoplastic disease which comprises: (a) obtaining a biol. sample from the subject; (b) contacting the sample with an agent that detects the presence of an extracellular domain of nARIA (CRD-neuregulin) or an isoform thereof; (c) measuring the amt. of agent bound by the sample; (d) comparing the amt. of agent bound measured in step (c) with the amt. of agent bound by a std. normal sample, a higher amt. bound by the sample from the subject being indicative of the subject having or being predisposed to developing a neoplastic disease. One embodiment of this invention is a method for maintaining synaptic connections between a neuron and a target cell comprising contacting the target cell with an nARIA polypeptide or a nucleic acid mol. encoding nARIA in an amt. sufficient to induce the formation of a synaptic junction.

IT 9005-49-6, Heparin sulfate, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nARIA vs. ARIA affinity for; A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses in diagnosis and maintaining synaptic connections)

L76 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:744967 CAPLUS

DOCUMENT NUMBER: 130:839

TITLE: Compositions and methods of therapy for
IGF-I-responsive conditions

INVENTOR(S): Scharschmidt, Bruce F.; Gorio, Alfredo; Muller,
Eugenio E.

PATENT ASSIGNEE(S): Chiron Corp., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850062	A1	19981112	WO 1998-US9273	19980506
W:	AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9873707	A1	19981127	AU 1998-73707	19980506
EP 1015019	A1	20000705	EP 1998-921004	19980506
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002507193	T2	20020305	JP 1998-548467	19980506

US 2003100505 A1 20030529 US 2002-279343 20021024
PRIORITY APPLN. INFO.: IT 1997-MI1042 A 19970506
WO 1998-US9273 W 19980506
US 1999-423161 B1 19991101

AB Compns. and methods useful in therapy for IGF-I (insulin-like growth factor-I)-responsive conditions in a mammal are provided. The method comprises concurrent therapy with both IGF-I or a variant thereof and at least one GAG to promote a desired therapeutic response with respect to a particular IGF-I-responsive condition. Concurrent therapy is achieved by administering to a mammal a single pharmaceutical compn. contg. both IGF-I (or a variant thereof) and at least one GAG according to a dosing regimen. Alternatively, IGF-I or a variant thereof and at least one GAG can be administered as two sep. pharmaceutical compns. A pharmaceutical compn. comprising IGF-I or a variant thereof and at least one GAG for use in the IGF-I and GAG therapy is also provided. In expts. it was shown that compns. of rhIGF-I and glucosaminoglycans are effective in promoting desired therapeutic treatment effects in the animal model of ALS and **spinal muscular atrophy**.

IT 9005-49-6, Heparin, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapy for insulin like growth factor-I-responsive conditions)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:485092 CAPLUS

DOCUMENT NUMBER: 129:104688

TITLE: Methods and substances for elevating the concentration of free insulin-like growth factor in vivo, and methods for screening the substances for clinical use
INVENTOR(S): Sakano, Katsuichi; Higashihashi, Nobuyuki; Hashimoto, Ryuji

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829451	A1	19980709	WO 1997-JP4881	19971226
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GM, GW, HU, ID, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9878910	A1	19980731	AU 1998-78910	19971226
EP 965596	A1	19991222	EP 1997-949250	19971226
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
NO 9902785	A	19990827	NO 1999-2785	19990608
US 6428781	B1	20020806	US 1999-331851	19990628
US 2003170240	A1	20030911	US 2002-173805	20020619

PRIORITY APPLN. INFO.:

JP 1996-349968 A 19961227

WO 1997-JP4881 W 19971226

US 1999-331851 A3 19990628

AB Disclosed are (1) methods of increasing the in vivo concn. of insulin-like

growth (IGF) by freeing the IGF from the IGF-IGFBP (IGF binding protein), (2) method of increasing the in vivo concn. of IGF-IGFBP concn. from the IGF-IGFBP-ALS (acid labile subunit) complex, and (3) methods for screening the substances that increase the in vivo concn. of IGF or IGF-IGFBP from their resp. precursors. Among 34 chem. compds. tested in vitro, ellagic acid, aclacinomycin A, and heparin were most effective on inhibiting the binding between IGF-II and IGFBP 3. Both human IGF-II[27-Tyr.fwdarw.Leu,43-Val.fwdarw.Leu] and rabbit anti-rat IGFBP 3 were used to demonstrated their ability to increase the free IGF-I blood level in SD. rats. The substances are useful as a prophylactics or therapeutics for diseases, e.g., diabetes, amyotrophic **lateral sclerosis**, and osteoporosis, that can be treated by IGF.

IT 9005-49-6, Heparin, biological studies

RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(IGF-II-IGFBP 3 binding inhibition by; methods and substances for elevating concn. of free insulin-like growth factor in vivo, and methods for screening substances for clin. use)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:197424 CAPLUS

DOCUMENT NUMBER: 128:266268

TITLE: Identification of agents that protect against inflammatory injury to neurons

INVENTOR(S): Giulian, Dana J.

PATENT ASSIGNEE(S): Baylor College of Medicine, USA; Giulian, Dana J.

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811923	A1	19980326	WO 1997-US16999	19970919
W: AU, CA, JP, US, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6071493	A	20000606	US 1996-717551	19960920
US 6043283	A	20000328	US 1997-870967	19970606
AU 9745894	A1	19980414	AU 1997-45894	19970919
AU 738509	B2	20010920		
EP 1051195	A1	20001115	EP 1997-944385	19970919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002504988	T2	20020212	JP 1998-514998	19970919
PRIORITY APPLN. INFO.:				
			US 1996-717551	A2 19960920
			US 1997-870967	A2 19970606
			WO 1997-US16999	W 19970919

OTHER SOURCE(S): MARPAT 128:266268

AB Methods are disclosed for identifying agents that inhibit the toxic effects of neurotoxins on neurons from plaque component-activated mononuclear phagocytes. Also disclosed are methods for identifying agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of mononuclear phagocytes, and plaque component-induced neurotoxicity of mononuclear phagocytes. The invention is also directed to agents and pharmaceutical compns. obtained by the identification methods described. Addnl., the invention describes methods for using tyramine compds. to inhibit the toxic effects of neurotoxins and methods to treat and diagnose neurodegenerative diseases and disorders.

IT 9005-49-6, Heparin sulfate, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(identification of agents that protect against inflammatory injury to neurons)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:180841 CAPLUS

DOCUMENT NUMBER: 128:239488

TITLE: Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications

INVENTOR(S): Lai, Ching-San

PATENT ASSIGNEE(S): Medinox, Inc., USA; Lai, Ching-San

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811066	A1	19980319	WO 1997-US15324	19970828
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9741725	A1	19980402	AU 1997-41725	19970828
AU 746790	B2	20020502		
EP 927159	A1	19990707	EP 1997-939694	19970828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
CN 1230178	A	19990929	CN 1997-197797	19970828
JP 2002511837	T2	20020416	JP 1998-513688	19970828
KR 2000035992	A	20000626	KR 1999-7001945	19990309
PRIORITY APPLN. INFO.:			US 1996-25867P	P 19960910
			US 1997-899087	A2 19970723
			US 1996-25867	A 19960910
			WO 1997-US15324	W 19970828

OTHER SOURCE(S): MARPAT 128:239488

AB A new class of drugs is provided for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Dithiocarbamates are linked to the surface of a macromol. (e.g. albumin), either by using crosslinking reagents or by non-specific binding, to produce polydithiocarbamate-macromol.-contg. compns. Combination therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of NO synthase expression. Magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct vol. in ischemic stroke or heart attack situations. Such methods employ iron-contg. complexes of a compn. comprising a dithiocarbamate and a macromol. as contrast agents. Prepn. of a reaction product of bovine serum albumin with N-methyl-D-glucamine dithiocarbamate is described.

IT 9005-49-6D, Heparin, dithiocarbamate reaction products, biological

studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polydithiocarbamate-contg. macromols. for therapeutic and diagnostic applications)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L76 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:394181 CAPLUS

DOCUMENT NUMBER: 125:49359

TITLE: Use of receptor agonists to stimulate superoxide dismutase activity

INVENTOR(S): Marklund, Stefan L.; Straalin, Pontus

PATENT ASSIGNEE(S): Swed.

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9614060	A1	19960517	WO 1995-IB979	19951103
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9537082	A1	19960531	AU 1995-37082	19951103
PRIORITY APPLN. INFO.:			DK 1994-1283	19941104
			WO 1995-IB979	19951103

AB The present invention relates to the use of a substance for the manuf. of a compn. for stimulating the release of extracellular superoxide dismutase (EC-SOD) from cells or stimulating the synthesis of EC-SOD in cells. In particular, the invention relates to the use of a substance for the manuf. of a compn. for prophylaxis or treatment of a disease or disorder connected with the presence of formation of superoxide radicals and other toxic intermediates derived from the superoxide radical. Further, the invention relates to a method for detg. the effect of a substance with respect to stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells and to substances which have been selected by the method. Within the scope of the invention is a method of preventing, diminishing, controlling, or inhibiting a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical in a patient who has been established to have a high risk of developing a such disease or disorder, or who has developed such a disease or disorder, the method comprising administering an effective amt. of a substance which is capable of stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells. SOD isoenzyme levels were detd. for a variety of human tissues and for the blood vessel wall of man and other mammals. Also reported is the reaction of cultured cells to a variety of factors (inflammation-related substances, vasoactive substances, growth factors, etc.).

IT 9005-49-6, Heparin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(superoxide dismutase stimulation with receptor agonists and therapeutic use)

L76 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1991:574647 CAPLUS

DOCUMENT NUMBER: 115:174647

TITLE: Inhibition of cell growth by keratin sulfate, chondroitin sulfate, dermatan sulfate, and other proteoglycans

INVENTOR(S): Snow, Diane M.; Silver, Jerry; Harel, Adrian; Roufa, Dikla

PATENT ASSIGNEE(S): Case Western Reserve University, USA; Gliotech, Inc.

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9106303	A1	19910516	WO 1990-US6189	19901026
W: AU, BB, BG, BR, CA, DK, ES, FI, HU, JP, KR, LK, MC, MG, MW, NO, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
CA 2071898	AA	19910428	CA 1990-2071898	19901026
AU 9168726	A1	19910531	AU 1991-68726	19901026
EP 493533	A1	19920708	EP 1990-917627	19901026
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 06502840	T2	19940331	JP 1991-500439	19901026
PRIORITY APPLN. INFO.:			US 1989-428374	19891027
			WO 1990-US6189	19901026

AB Proteoglycans such as keratan sulfate (I), chondroitin sulfate (II), dermatan sulfate (III), heparan sulfate (IV), heparin (V), and hyaluronic acid (VI) are used to prevent neurite outgrowth, i.e. axonal growth, or nerve regeneration, or glial cell migration, invasion, or regeneration. Inhibitors and antagonists of proteoglycans may also be used to promote nerve growth or glial cell migration or invasion. Such inhibitors and antagonists include antibodies, degradative enzymes, lectins, and disaccharide antagonists of the receptors for I, II, III, IV, V, or VI. Chick E-6 dorsal root ganglia (DRG) cells were cultured on nitrocellulose treated with a II-proteoglycan in the presence of nerve growth factor. DRG neurite outgrowth was completely inhibited by 0.4 mg/mL II-proteoglycan.

IT 9005-49-6D, Heparin, derivs.
RL: BIOL (Biological study)
(neurite outgrowth inhibition by)

L76 ANSWER 15 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2003:243831 USPATFULL

TITLE: Composition of an endogenous insulin-like growth factor-II derivative

INVENTOR(S): Sakano, Katsuichi, Tokyo, JAPAN
Higashihashi, Nobuyuki, Tokyo, JAPAN
Hashimoto, Ryuji, Tokyo, JAPAN

PATENT ASSIGNEE(S): DAIICHI PHARMACEUTICAL CO., LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170240	A1	20030911
APPLICATION INFO.:	US 2002-173805	A1	20020619 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-331851, filed on 28 Jun		

1999, GRANTED, Pat. No. US 6428781 A 371 of
International Ser. No. WO 1997-JP4881, filed on 26 Dec
1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-349968	19961227
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1522	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The effects of endogenous insulin-like growth factor can be appreciated by administering compounds capable of increasing free IGF in living bodies. Compounds are described which can elevate the concentration of unbound IGF by converting endogenous IGF (insulin-like growth factor) into free, biologically active IGF or elevating the concentration of the complex of IGF and IGFBP (insulin-like growth factor binding protein) in living bodies. Medicaments can be prepared containing these compounds or these compounds may be used in methods for the prevention and or treatment of IGF-responsive diseases such as diabetes, amyotrophic lateral sclerosis, or osteoporosis.

IT 9005-49-6, Heparin, biological studies
(IGF-II-IGFBP 3 binding inhibition by; methods and substances for elevating concn. of free insulin-like growth factor in vivo, and methods for screening substances for clin. use)

L76 ANSWER 16 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2003:146758 USPATFULL
TITLE: Compositions and methods of therapy for
IGF-I-responsive conditions
INVENTOR(S): Scharschmidt, Bruce F., San Francisco, CA, UNITED
STATES
Gorio, Alfredo, Milano, ITALY
Muller, Eugenio E., Milano, ITALY
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, 94608 (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003100505	A1	20030529
APPLICATION INFO.:	US 2002-279343	A1	20021024 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-423161, filed on 1 Nov 1999, ABANDONED A 371 of International Ser. No. WO 1998-US9273, filed on 6 May 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Chiron Corporation, 4560 Horton Street, Emeryville, CA, 94608		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1002		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods useful in therapy for IGF-I-responsive conditions in a mammal are provided. The method comprises concurrent therapy with both IGF-I or a variant thereof and at least one GAG to promote a desired therapeutic response with respect to a particular IGF-I-responsive condition. Concurrent therapy is achieved by

administering to a mammal a single pharmaceutical composition containing both IGF-I (or a variant thereof) and at least one GAG according to a dosing regimen. Alternatively, IGF-I or a variant thereof and at least one GAG can be administered as two separate pharmaceutical compositions. A pharmaceutical composition comprising IGF-I or a variant thereof and at least one GAG for use in the IGF-I and GAG therapy is also provided.

IT 9005-49-6, Heparin, biological studies

(therapy for insulin like growth factor-I-responsive conditions)

L76 ANSWER 17 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2003:44871 USPATFULL

TITLE: Production of radial glial cells

INVENTOR(S): Weiss, Samuel, Calgary, CANADA

Gregg, Christopher, Calgary, CANADA

PATENT ASSIGNEE(S): Stem Cell Therapeutics Inc., Calgary, AB, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032181	A1	20030213
APPLICATION INFO.:	US 2002-196549	A1	20020717 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	CA 2001-2364095	20011130
	US 2001-307096P	20010720 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1123	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of producing radial glial cells from neural stem cells, particularly by contacting neural stem cells with epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2) and/or TGF.alpha.. Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can optionally be added to enhance the effect of EGF, FGF-1 or TGF.alpha.. Also provided are methods of producing radial glial cells from ependymal cells, as well as methods of proliferating ependymal cells.

IT 9005-49-6, Heparin sulfate, biological studies

(glial cells prodn. in presence of growth factors and; prodn. of radial glial cells from neural stem cells and ependymal cells in presence of growth factors and therapeutic applications)

L76 ANSWER 18 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2003:17441 USPATFULL

TITLE: Method of producing region-specific neurons from human neuronal stem cells

INVENTOR(S): Wu, Ping, League City, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003013193	A1	20030116
APPLICATION INFO.:	US 2002-176971	A1	20020619 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300344P	20010622 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415,
MINNEAPOLIS, MN, 55458
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of priming neural stem cells in vitro by adhesively culturing
in a mixture of basic fibroblast growth factor, laminin and heparin to
differentiate into specific neuronal phenotypes, including cholinergic,
glutamatergic and GABAergic neurons, in a region-specific manner, when
transplanted in vivo.

IT 9005-49-6, Heparin, biological studies
(method of producing region-specific neurons from human neuronal stem
cells)

L76 ANSWER 19 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2003:240396 USPATFULL

TITLE: Oligosaccharides, their preparation and pharmaceutical
compositions containing them

INVENTOR(S): Mourier, Pierre, Charenton le Pont, FRANCE
Perrin, Elisabeth, Evrenus, FRANCE
Stutzmann, Jean-marie, Villecresnes, FRANCE
Viskov, Christian, Ris Orangis, FRANCE
Wahl, Florence, Paris, FRANCE

PATENT ASSIGNEE(S): Aventis Pharma, Cedex, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6617316	B1	20030909
APPLICATION INFO.:	US 2000-693243		20001020 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-13182	19991022
	US 2000-174647P	20000105 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Fonda, Kathleen K.

LEGAL REPRESENTATIVE: Newman, Irving

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 798

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to oligosaccharides of formula: ##STR1##

to mixtures thereof, to diastereoisomers thereof, to a process for
preparing them, to pharmaceutical compositions containing them, and to
their use in preventing or treating a disease associated with an
inflammatory process involving the production of nitric oxide.

IT 9005-49-6, Heparin, reactions
(prepn. of uronic acid-contg. oligosaccharides as antiinflammatory
agents)

L76 ANSWER 20 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2002:272935 USPATFULL

TITLE: Novel differentiation inducing process of embryonic
stem cell to ectodermal cell and its use

INVENTOR(S): Sasai, Yoshiki, Kyoto, JAPAN
Nishikawa, Shin-Ichi, Kyoto, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151056	A1	20021017
APPLICATION INFO.:	US 2001-855587	A1	20010516 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-144059	20000516
	JP 2000-290819	20000925
	US 2000-257049P	20001220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112

NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4056

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for inducing differentiation of an embryonic stem cell into an ectodermal cell and an ectoderm-derived cell, which comprises culturing the embryonic stem cell under non-aggregation conditions; a medium and a medium supernatant used in the method; an agent for inducing differentiation used in the method; a stroma cell or a stroma cell-derived factor having activity of inducing differentiation in the method; an antibody which specifically recognizes the stroma cell; an antigen which recognizes the antibody; a cell induced by the method; a method for evaluating or screening a substance relating to the regulation in a differentiation step from an embryonic stem cell into an ectodermal cell or an ectoderm-derived cell by carrying out the method; and a medicament comprising the stroma cell, the stroma cell-derived cell, the antibody, the antigen or the cell.

IT 9005-49-6, Heparin, biological studies
(novel method for inducing differentiation of embryonic stem cells into ectodermal cells and use)

L76 ANSWER 21 OF 35 USPATFULL on STN
ACCESSION NUMBER: 2002:72873 USPATFULL
TITLE: Novel therapeutic use of low molecular weight heparins
INVENTOR(S): Stutzmann, Jean-Marie, Villecresnes, FRANCE
Uzan, Andre, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040013	A1	20020404
APPLICATION INFO.:	US 2001-881267	A1	20010614 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-FR3109, filed on 13 Dec 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-15919	19981217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	331	

AB The invention concerns the use of low molecular weight heparin for preventing and/or treating motor neuron diseases.

L76 ANSWER 22 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2002:32546 USPATFULL

TITLE: Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof

INVENTOR(S): Mourier, Pierre, Charenton Le Pont, FRANCE
Perrin, Elisabeth, Evreux, FRANCE
Viskov, Christian, Ris Orangis, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019368	A1	20020214
	US 6608042	B2	20030819
APPLICATION INFO.:	US 2001-817428	A1	20010326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2000-3910	20000328
	US 2000-205026P	20000518 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	983	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions containing as an active ingredient at least one oligosaccharide of formula:
##STR1##to novel oligosaccharides of formula (I), to mixtures thereof and to methods for their preparation.
IT 9005-49-6, Heparin, reactions
(prepn. of uronic acid-contg. oligosaccharides from heparin as antiinflammatory agents)

L76 ANSWER 23 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2002:290736 USPATFULL

TITLE: Identification of agents that protect against inflammatory injury to neurons

INVENTOR(S): Giuliani, Dana, Houston, TX, United States

PATENT ASSIGNEE(S): Baylor College of Medicine, Houston, TX, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475745	B1	20021105
APPLICATION INFO.:	US 1997-922889		19970903 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-717551, filed on 20 Sep 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Turner, Sharon		
LEGAL REPRESENTATIVE:	Vinson & Elkins L.L.P.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	92 Drawing Figure(s); 38 Drawing Page(s)		
LINE COUNT:	2755		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.

IT 9005-49-6, Heparin sulfate, biological studies
(identification of agents that protect against inflammatory injury to neurons)

L76 ANSWER 24 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2002:194555 USPATFULL
TITLE: Composition of an endogenous insulin-like growth factor-II derivative
INVENTOR(S): Sakano, Katsuichi, Tokyo, JAPAN
Higashihashi, Nobuyuki, Tokyo, JAPAN
Hashimoto, Ryuji, Tokyo, JAPAN
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Tokyo, JAPAN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6428781	B1	20020806
	WO 9829451		19980709
APPLICATION INFO.:	US 1999-331851		19990628 (9)
	WO 1997-JP4881		19971226
			19990628 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-349968	19961227
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kemmerer, Elizabeth	
ASSISTANT EXAMINER:	Bunner, Bridget E.	
LEGAL REPRESENTATIVE:	Sughrue Mion, PLLC	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1427	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The effects of endogenous insulin-like growth factor can be appreciated by administering compounds capable of increasing free IGF in living bodies. Compounds are described which can elevate the concentration of unbound IGF by converting endogenous IGF (insulin-like growth factor) into free, biologically active IGF or elevating the concentration of the complex of IGF and IGFBP (insulin-like growth factor binding protein) in living bodies. Medicaments can be prepared containing these compounds or these compounds may be used in methods for the prevention and or treatment of IGF-responsive diseases such as diabetes, amyotrophic lateral sclerosis, or osteoporosis.

IT 9005-49-6, Heparin, biological studies
(IGF-II-IGFBP 3 binding inhibition by; methods and substances for elevating concn. of free insulin-like growth factor in vivo, and methods for screening substances for clin. use)

L76 ANSWER 25 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2001:139285 USPATFULL
TITLE: IDENTIFICATION OF AGENTS THAT PROTECT AGAINST

INVENTOR(S): INFLAMMATORY INJURY TO NEURONS
GIULIAN, DANA, HOUSTON, TX, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016327	A1	20010823
	US 6475742	B2	20021105
APPLICATION INFO.:	US 1997-923055	A1	19970903 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-717551, filed on 20 Sep 1996, GRANTED, Pat. No. US 6071493		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	VINSON & ELKINS L.L.P., ATTN: DOCKET SPECIALIST, 2300 FIRST CITY TOWER, HOUSTONLPHIA, TX, 770026760		
NUMBER OF CLAIMS:	99		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Page(s)		
LINE COUNT:	2790		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.

IT 9005-49-6, Heparin sulfate, biological studies
(identification of agents that protect against inflammatory injury to neurons)

L76 ANSWER 26 OF 35 USPATFULL on STN

ACCESSION NUMBER: 2001:139284 USPATFULL
TITLE: IDENTIFICATION OF AGENTS THAT PROTECT AGAINST
INFLAMMATORY INJURY TO NEURONS
INVENTOR(S): GIULIAN, DANA, HOUSTON, TX, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016326	A1	20010823
	US 6451544	B2	20020917
APPLICATION INFO.:	US 1997-922930	A1	19970903 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-717551, filed on 20 Sep 1996, GRANTED, Pat. No. US 6071493		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	VINCE & ELKINS, L.L.P., ATTN: DOCKET SPECIALIST, 2300 FIRST CITY TOWER, 1001 FANNIN STREET, HOUSTON, TX, 770026760		
NUMBER OF CLAIMS:	99		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Page(s)		
LINE COUNT:	2792		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the

method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.

IT 9005-49-6, Heparin sulfate, biological studies
(identification of agents that protect against inflammatory injury to neurons)

L76 ANSWER 27 OF 35 USPATFULL on STN
ACCESSION NUMBER: 2000:70424 USPATFULL
TITLE: Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
INVENTOR(S): Giulian, Dana, Houston, TX, United States
PATENT ASSIGNEE(S): Baylor College of Medicine, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071493		20000606
APPLICATION INFO.:	US 1996-717551		19960920 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Corder, Timothy S.Vinson & Elkins LLP		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	92 Drawing Figure(s); 38 Drawing Page(s)		
LINE COUNT:	2660		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation (hereinafter "complex formation"). The methods include the steps of contacting a mononuclear phagocyte with a plaque component to stimulate complex formation and adding an agent suspected of inhibiting complex formation, measuring complex formation, and comparing complex formation to a measured control, wherein the reduction of complex formation compared to the control results in detection of an agent that inhibits complex formation. The mononuclear phagocytes may be from mammalian brain. The plaque component may be coupled to a solid support.

IT 9005-49-6, Heparin sulfate, biological studies
(identification of agents that protect against inflammatory injury to neurons)

L76 ANSWER 28 OF 35 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1997:308923 BIOSIS
DOCUMENT NUMBER: PREV199799616726
TITLE: Effects of low doses of glycosaminoglycans and insulin-like growth factor-I on **motor neuron disease** in wobbler mouse.
AUTHOR(S): Vergani, Letizia; Finco, Cristina; Di Giulio, Anna Maria; Muller, E. E.; Gorio, Alfredo [Reprint author]
CORPORATE SOURCE: Lab. Res. Pharmacol. Neurodegenerative Disorders, Dep. Pharmacol. Chemotherapy Med. Toxicol., Univ. Milano, Via Vanvitelli 32, 20124 Milano, Italy
SOURCE: Neuroscience Letters, (1997) Vol. 228, No. 1, pp. 41-44. CODEN: NELED5. ISSN: 0304-3940.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Jul 1997
Last Updated on STN: 26 Jul 1997

ABSTRACT: In this study we examined the effects of insulin-like growth factor-I (IGF-I) and of glycosaminoglycans (GAGs) on the progressive **motor ***neuron*** disease** in wobbler mice. After clinical diagnosis at age 3 weeks, mice received daily subcutaneous injections of IGF-I, or GAGs, or saline for 3 weeks. The histometric analysis revealed that biceps muscle fiber diameter was reduced in wobbler mice and that treatments with GAGs and IGF-I prevented such a drop. The number of atrophic small fibers was markedly reduced and that of the larger ones augmented. No effects on body growth and biceps muscle weight were observed. The combined AChE-silver staining revealed that both treatments promoted intramuscular axonal sprouting. The typical decline of grip strength in wobbler mice was also prevented. This study suggests that GAGs and IGF-I administrations can retard the onset of motor deficit, and reduce muscle atrophy in wobbler mice.

CONCEPT CODE: Biochemistry studies - Proteins, peptides and amino acids 10064

Biochemistry studies - Carbohydrates 10068

Pathology - Necrosis 12510

Pathology - Therapy 12512

Endocrine - General 17002

Endocrine - Neuroendocrinology 17020

Muscle - Physiology and biochemistry 17504

Muscle - Pathology 17506

Integumentary system - General and methods 18501

Nervous system - Physiology and biochemistry 20504

Nervous system - Pathology 20506

Pharmacology - Endocrine system 22016

Pharmacology - Muscle system 22022

Pharmacology - Neuropharmacology 22024

Routes of immunization, infection and therapy 22100

Development and Embryology - Morphogenesis 25508

Laboratory animals - General 28002

INDEX TERMS:

Major Concepts

Animal Care; Biochemistry and Molecular Biophysics;
Development; Endocrine System (Chemical Coordination and Homeostasis); Integumentary System (Chemical Coordination and Homeostasis); Muscular System (Movement and Support); Nervous System (Neural Coordination); Pharmacology

INDEX TERMS:

Chemicals & Biochemicals

INSULIN-LIKE GROWTH FACTOR-I; HEPARIN

INDEX TERMS:

Miscellaneous Descriptors

ADMINISTRATION; ANIMAL MODEL; BICEPS MUSCLE;
GLYCOSAMINOGLYCANS; HEPARIN; INSULIN-LIKE GROWTH FACTOR-I; INTRAMUSCULAR AXONAL SPROUTING; LOW DOSES;
MOTOR DEFICIT; MOTOR NEURON DEGENERATION; **MOTOR NEURON DISEASE**; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE STRENGTH; MUSCLE WEIGHT; MUSCULAR SYSTEM; NERVE ATROPHY; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASE; PHARMACOLOGY; SUBCUTANEOUS INJECTION; WOBBLER MOUSE

ORGANISM:

Classifier

Muridae 86375

Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

Muridae

Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER:

67763-96-6 (INSULIN-LIKE GROWTH FACTOR-I)

9005-49-6 (HEPARIN)

ACCESSION NUMBER: 1986:120194 BIOSIS
DOCUMENT NUMBER: PREV198681030610; BA81:30610
TITLE: MULTIPLE RETINAL MUSCULAR AND CUTANEOUS CHOLESTEROL EMBOLI
A CASE WITH PROGRESSIVE ENCEPHALOPATHY.
AUTHOR(S): BUGÉ A [Reprint author]; VINCENT D; RANCUREL G; BAUDRIMONT
M; DUBAS F; HAUW J-J
CORPORATE SOURCE: CLIN NEUROL, HOPITAL DE LA SALPETRIERE, 47 BLVD
DEL'HOPITAL, F-75651 PARIS CEDEX 13, FR
SOURCE: Revue Neurologique (Paris), (1985) Vol. 141, No. 8-9, pp.
578-582.
CODEN: RENEAM. ISSN: 0035-3787.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: FRENCH
ENTRY DATE: Entered STN: 25 Apr 1986
Last Updated on STN: 25 Apr 1986

ABSTRACT: A 73 year-old man experienced left monocular blindness and transient right hand clumsiness. A left carotid arteriogram was performed 4 days after admission. Immediately following arteriography, there was a right hemiparesia and dysphasia. After 24 hours, the abnormalities resolved. The patient was treated with heparin. During the following weeks, he became gradually drowsy and confused. Pseudo-bulbar palsy and astasia appeared after a fluctuating but progressive neurological course. The combination of systemic symptoms, high sedimentation rate, renal failure, livedo reticularis and purple toes suggested necrotizing angiitis. With corticosteroid treatment, there was a slight improvement of systemic symptoms. Cholesterol emboli were seen in both fundi. Cholesterol embolization was proved by identifying the biconcave cholesterol crystal clefts in muscle and skin biopsies. The subsequent course was marked by continuous neurological deterioration. The patient became stuporous and died 7 months after admission. Despite the lack of central nervous system pathological study, the clinical picture was highly suggestive of cerebral cholesterol embolism. A few cases have been reported, with only eight well-documented clinical descriptions. Clinical signs and symptoms were closely similar to those of the present case. Anticoagulant therapy of cholesterol emboli has been unsuccessful. In the present case the onset of embolization was temporally related to anticoagulation.

CONCEPT CODE: Biochemistry studies - Sterols and steroids 10067
Biochemistry studies - Carbohydrates 10068
Anatomy and Histology - Experimental anatomy 11104
Pathology - Necrosis 12510
Metabolism - Sterols and steroids 13008
Cardiovascular system - Blood vessel pathology 14508
Endocrine - Adrenals 17004
Muscle - Pathology 17506
Integumentary system - Pathology 18506
Sense organs - Pathology 20006
Nervous system - Pathology 20506
Pharmacology - Clinical pharmacology 22005
Pharmacology - Cardiovascular system 22010
Pharmacology - Endocrine system 22016

INDEX TERMS: Major Concepts
Cardiovascular Medicine (Human Medicine, Medical
Sciences); Dermatology (Human Medicine, Medical
Sciences); Endocrine System (Chemical Coordination and
Homeostasis); Metabolism; Muscular System (Movement and
Support); Neurology (Human Medicine, Medical Sciences);
Pharmacology; Sense Organs (Sensory Reception)

INDEX TERMS: Miscellaneous Descriptors
HUMAN CORTICOSTEROID HORMONE-DRUG HEPARIN
CARDIOVASCULAR-DRUG ANTICOAGULANT-DRUG DYSPHASIA
HEMIPARESIS NECROTIZING ANGIITIS

ORGANISM: Classifier
Hominidae 86215

Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates,
Vertebrates

REGISTRY NUMBER: 57-88-5 (CHOLESTEROL)
9005-49-6 (HEPARIN)

L76 ANSWER 30 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003247308 EMBASE

TITLE: Strokes, thromboembolic events, and IVIg: Rare incidents
blemish an excellent safety record.

AUTHOR: Dalakas M.C.; Clark W.M.

CORPORATE SOURCE: Dr. M.C. Dalakas, Neuromuscular Diseases Section, NINDS,
NIH, 10 Center Dr., Bethesda, MD 20892-1382, United States.
dalakasm@ninds.nih.gov

SOURCE: Neurology, (10 Jun 2003) 60/11 (1736-1737).
Refs: 10

ISSN: 0028-3878 CODEN: NEURAI

COUNTRY: United States

DOCUMENT TYPE: Journal; Editorial

FILE SEGMENT: 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:

*stroke: DT, drug therapy

*stroke: PC, prevention

*stroke: SI, side effect

*occlusive cerebrovascular disease: DT, drug therapy

*occlusive cerebrovascular disease: PC, prevention

*occlusive cerebrovascular disease: SI, side effect

thromboembolism: DT, drug therapy

thromboembolism: PC, prevention

thromboembolism: SI, side effect

autoimmune disease: DT, drug therapy

neuromuscular disease: DT, drug therapy

drug efficacy

drug safety

motor neuron disease: DT, drug therapy

Guillain Barre syndrome: DT, drug therapy

chronic inflammatory demyelinating polyneuropathy: DT, drug
therapy

myasthenia: DT, drug therapy

dermatomyositis: DT, drug therapy

Eaton Lambert syndrome: DT, drug therapy

stiff man syndrome: DT, drug therapy

drug mechanism

complement activation

macrophage

side effect: SI, side effect

headache: SI, side effect

chill: SI, side effect

myalgia: SI, side effect

low back pain: SI, side effect

thorax pain: SI, side effect

aseptic meningitis: SI, side effect

rash: SI, side effect

anaphylaxis: SI, side effect

immunoglobulin A deficiency

kidney tubule necrosis: SI, side effect
kidney disease
high risk patient
vascular disease
treatment outcome
fibrinolytic therapy
disease predisposition
muscle weakness
immobilization
wheelchair
lung embolism: SI, side effect
drug infusion
antibody blood level
capillary flow
hypergammaglobulinemia
hypercholesterolemia
risk factor
blood flow velocity
hydration
thrombocytosis
diabetes mellitus
prophylaxis
echography
low drug dose
human
clinical trial
editorial
priority journal
Drug Descriptors:
*immunoglobulin: AE, adverse drug reaction
*immunoglobulin: CT, clinical trial
*immunoglobulin: CB, drug combination
*immunoglobulin: DT, drug therapy
*immunoglobulin: PD, pharmacology
*immunoglobulin: IV, intravenous drug administration
autoantibody: EC, endogenous compound
complement: EC, endogenous compound
cytokine: EC, endogenous compound
Fc receptor: EC, endogenous compound
immunoglobulin A: EC, endogenous compound
tissue plasminogen activator: DT, drug therapy
tissue plasminogen activator: PD, pharmacology
placebo
immunoglobulin G: EC, endogenous compound
fibrinogen: EC, endogenous compound
phospholipid antibody: EC, endogenous compound
acetylsalicylic acid: DT, drug therapy
acetylsalicylic acid: PD, pharmacology
nimodipine: DT, drug therapy
nimodipine: PD, pharmacology
anticoagulant agent: DT, drug therapy
anticoagulant agent: PD, pharmacology
urokinase: DT, drug therapy
urokinase: PD, pharmacology
heparin: DT, drug therapy
heparin: PD, pharmacology

low molecular weight heparin: CB, drug combination

low molecular weight heparin: DT, drug therapy

low molecular weight heparin: PD, pharmacology

CAS REGISTRY NO.: (immunoglobulin) 9007-83-4; (complement) 9007-36-7; (tissue plasminogen activator) 105913-11-9; (immunoglobulin G) 97794-27-9; (fibrinogen) 9001-32-5; (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1;

(nimodipine) 66085-59-4; (urokinase) 139639-24-0; (heparin)
37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5
CHEMICAL NAME: Aspirin

L76 ANSWER 31 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2002190914 EMBASE
TITLE: Caesarean section conducted under subarachnoid block in two
sisters with spinal muscular atrophy.
AUTHOR: Harris S.J.; Moaz K.
CORPORATE SOURCE: S.J. Harris, Queen Elizabeth Hospital, Gayton Road,
Norfolk, PE30 4ET, United Kingdom.
angela.kent@klshosp.anglox.nhs.uk
SOURCE: International Journal of Obstetric Anesthesia, (2002) 11/2
(125-127).
Refs: 10
ISSN: 0959-289X CODEN: IOANER
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 024 Anesthesiology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT:

Spinal muscular atrophy is a rare chronic neurological condition characterised by degeneration of the anterior horn cell. Experience with the anaesthetic management of the pregnant patient with this condition is limited. We report the clinical details of two wheelchair-bound sisters, who underwent elective caesarean section within a few weeks of one another. Both patients were safely managed with subarachnoid anaesthesia without any deterioration of their underlying neurological condition. It is hoped that this report will add to the evidence that subarachnoid anaesthesia can safely be used for caesarean section in chronic neurological conditions and, in particular, spinal muscular atrophy.
.COPYRG. 2002 published by Elsevier Science Ltd.

CONTROLLED TERM: Medical Descriptors:
*spinal muscular atrophy
*cesarean section
*obstetric anesthesia
neurologic disease
elective surgery
general anesthesia
regional anesthesia
postoperative pain: CO, complication
postoperative pain: DT, drug therapy
postoperative pain: PC, prevention
subarachnoid space
chronic disease
thromboembolism: CO, complication
thromboembolism: DT, drug therapy
thromboembolism: PC, prevention
human
female
case report
adult
article
Drug Descriptors:
*bupivacaine: AD, drug administration
*bupivacaine: DO, drug dose
*bupivacaine: EI, epidural drug administration
morphine: AD, drug administration
morphine: DT, drug therapy
morphine: EI, epidural drug administration

morphine: IM, intramuscular drug administration
diclofenac: AD, drug administration
diclofenac: DT, drug therapy
diclofenac: RC, rectal drug administration
 low molecular weight heparin: DO, drug dose
 low molecular weight heparin: DT, drug therapy
 low molecular weight heparin: SC, subcutaneous drug
administration
 enoxaparin: DO, drug dose
 enoxaparin: DT, drug therapy
 enoxaparin: SC, subcutaneous drug administration
fentanyl: AD, drug administration
fentanyl: DO, drug dose
fentanyl: EI, epidural drug administration
anesthetic agent: AD, drug administration
anesthetic agent: DO, drug dose
anesthetic agent: EI, epidural drug administration
suxamethonium
rocuronium
neuromuscular blocking agent

CAS REGISTRY NO.: (bupivacaine) 18010-40-7, 2180-92-9, 55750-21-5; (morphine)
52-26-6, 57-27-2; (diclofenac) 15307-79-6, 15307-86-5;
(enoxaparin) 9041-08-1; (fentanyl) 437-38-7;
(suxamethonium) 306-40-1, 71-27-2; (rocuronium) 119302-91-9
CHEMICAL NAME: Clexane

L76 ANSWER 32 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2001277576 EMBASE
TITLE: Hodgkin's disease complicated by the nephrotic syndrome in
a man with Kugelberg-Welander disease.
AUTHOR: Thomson J.A.; Seymour J.F.; Wolf M.
CORPORATE SOURCE: M. Wolf, Div. of Haematology/Medical Oncology, Peter
MacCallum Cancer Institute, A'Beckett Street, Melbourne,
Vic. 8006, Australia
SOURCE: Leukemia and Lymphoma, (2001) 42/3 (561-566).
Refs: 23
ISSN: 1042-8194 CODEN: LELYEA
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
025 Hematology
028 Urology and Nephrology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:

A case of nephrotic syndrome due to minimal change glomerulonephritis complicating Hodgkin's disease in a man with a longstanding neurological disorder is presented. Treatment with combination chemotherapy resulted in a rapid improvement in the nephrotic syndrome, and complete remission of the Hodgkin's disease. Disease relapse occurred less than 12 months later without recurrence of the nephrotic syndrome and was refractory to further treatment. The association of minimal change glomerulonephritis with Hodgkin's disease and the possible pathogenesis of this association are discussed.

CONTROLLED TERM: Medical Descriptors:
*Hodgkin disease: DI, diagnosis
*Hodgkin disease: DT, drug therapy
*nephrotic syndrome: CO, complication
*nephrotic syndrome: DI, diagnosis
*nephrotic syndrome: DT, drug therapy

*nephrotic syndrome: ET, etiology
*Kugelberg Welander disease: DI, diagnosis
complication: CO, complication
minimal change glomerulonephritis: DI, diagnosis
neurologic disease
cancer combination chemotherapy
drug response
leukemia remission
cancer recurrence
recurrent disease
disease association
pathogenesis
kidney biopsy
laboratory diagnosis
human
male
case report
controlled study
human tissue
adult
article
priority journal
Drug Descriptors:

enoxaparin: DT, drug therapy

enoxaparin: SC, subcutaneous drug administration

dexamethasone: DT, drug therapy

allopurinol: DT, drug therapy

prednisolone: CB, drug combination

prednisolone: DT, drug therapy

cyclophosphamide: CB, drug combination

cyclophosphamide: DT, drug therapy

etoposide: CB, drug combination

etoposide: DT, drug therapy

procarbazine: CB, drug combination

procarbazine: DT, drug therapy

doxorubicin: CB, drug combination

doxorubicin: DT, drug therapy

bleomycin: CB, drug combination

bleomycin: DT, drug therapy

CAS REGISTRY NO.: (enoxaparin) 9041-08-1; (dexamethasone) 50-02-2;
(allopurinol) 315-30-0; (prednisolone) 50-24-8;
(cyclophosphamide) 50-18-0; (etoposide) 33419-42-0;
(procarbazine) 366-70-1, 671-16-9; (doxorubicin)
23214-92-8, 25316-40-9; (bleomycin) 11056-06-7

L76 ANSWER 33 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 1999203917 EMBASE

TITLE: [Report from the USA].

BERICHT AUS USA.

AUTHOR: Gakenheimer W.C.

CORPORATE SOURCE: Dr. W.C. Gakenheimer, 413 Stafford Road, Wilmington, DE
19803, United States

SOURCE: Pharmazeutische Industrie, (1999) 61/5 (449-452).

ISSN: 0031-711X CODEN: PHINAN

COUNTRY: Germany

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index

039 Pharmacy

LANGUAGE: German

CONTROLLED TERM: Medical Descriptors:

*drug packaging

*drug industry
food and drug administration
standardization
 amyotrophic lateral sclerosis
multiple sclerosis: DT, drug therapy
unstable angina pectoris: DT, drug therapy
oncogene neu
prostate cancer: DT, drug therapy
depression: DT, drug therapy
article
Drug Descriptors:
 mevinolin
 fluoxetine
protein c: EC, endogenous compound
ligand
glatiramer
 dalteparin: DT, drug therapy
prostate specific antigen: EC, endogenous compound
liposome
taxol
doxorubicin
betala interferon: DT, drug therapy
paroxetine
venlafaxine: DT, drug therapy
antineoplastic agent: DT, drug therapy
mdx 210
CAS REGISTRY NO.: (mevinolin) 75330-75-5; (fluoxetine) 54910-89-3,
56296-78-7, 59333-67-4; (protein c) 60202-16-6;
(glatiramer) 147245-92-9, 28704-27-0; (taxol) 33069-62-4;
(doxorubicin) 23214-92-8, 25316-40-9; (paroxetine)
61869-08-7; (venlafaxine) 93413-69-5
CHEMICAL NAME: (1) Copaxone; (2) Fragmin; (3) Mdx 210; (4) Paxil; (5)
Effexor; (6) Rebif; (7) Mevacor; (8) Prozac
COMPANY NAME: (1) Teva (Israel); (2) Pharmacia Upjohn (United States);
(3) Medarex (United States); (4) Smith Kline Beecham; (5)
Wyeth Ayerst; (6) Serono; (7) Merck; (8) Lilly; Neopharma

L76 ANSWER 34 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 96288534 EMBASE
DOCUMENT NUMBER: 1996288534
TITLE: Clinical pharmacology and therapeutics.
AUTHOR: Kochar M.S.; Campbell W.B.
CORPORATE SOURCE: Department of Medicine, Zablocki VA Medical Center, Medical
College of Wisconsin, Milwaukee, WI, United States
SOURCE: Wisconsin Medical Journal, (1996) 95/9 (645-646).
ISSN: 0043-6542 CODEN: WMJOA7
COUNTRY: United States
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
CONTROLLED TERM: Medical Descriptors:
*clinical pharmacology
abortion
 amyotrophic lateral sclerosis: DT, drug therapy
chickenpox: DT, drug therapy
chickenpox: PC, prevention
gastrointestinal toxicity: SI, side effect
general anesthesia

headache: SI, side effect
hepatitis a: PC, prevention
hepatitis a: DT, drug therapy
human
human immunodeficiency virus infection: DT, drug therapy
hypertension: DT, drug therapy
intramuscular drug administration
intravaginal drug administration
lactic acidosis: SI, side effect
migraine: DT, drug therapy
non insulin dependent diabetes mellitus: DT, drug therapy
obesity: DT, drug therapy
oral drug administration
osteoporosis: DT, drug therapy
short survey
subcutaneous drug administration
Drug Descriptors:
*alendronic acid: DT, drug therapy
*alendronic acid: PD, pharmacology
*anti human immunodeficiency virus agent: DT, drug therapy
*anti human immunodeficiency virus agent: CB, drug
combination
*anti human immunodeficiency virus agent: PD, pharmacology
*antidiabetic agent: AE, adverse drug reaction
*antidiabetic agent: DT, drug therapy
*antidiabetic agent: PD, pharmacology
*dexfenfluramine: PD, pharmacology
*dexfenfluramine: DT, drug therapy
*dipeptidyl carboxypeptidase inhibitor: CM, drug comparison
*dipeptidyl carboxypeptidase inhibitor: DT, drug therapy
*dipeptidyl carboxypeptidase inhibitor: PD, pharmacology
*losartan potassium: CM, drug comparison
*losartan potassium: DT, drug therapy
*losartan potassium: PD, pharmacology
abortive agent: AE, adverse drug reaction
abortive agent: PD, pharmacology
acarbose: AE, adverse drug reaction
acarbose: PD, pharmacology
acarbose: DT, drug therapy
angiotensin receptor antagonist: CM, drug comparison
angiotensin receptor antagonist: DT, drug therapy
angiotensin receptor antagonist: PD, pharmacology
biguanide: PD, pharmacology
biguanide: DT, drug therapy
biguanide: AE, adverse drug reaction
biguanide: CB, drug combination
bisphosphonic acid derivative: PD, pharmacology
bisphosphonic acid derivative: DT, drug therapy
chickenpox vaccine: DT, drug therapy
 dalteparin: DT, drug therapy
desflurane
 enoxaparin: DT, drug therapy
hepatitis a vaccine: DT, drug therapy
indinavir: CB, drug combination
indinavir: DT, drug therapy
indinavir: PD, pharmacology
inhalation anesthetic agent
 low molecular weight heparin: DT, drug therapy
metformin: PD, pharmacology
metformin: AE, adverse drug reaction
metformin: DT, drug therapy
metformin: CB, drug combination
methotrexate: AE, adverse drug reaction

methotrexate: PD, pharmacology
 misoprostol: PD, pharmacology
 misoprostol: AE, adverse drug reaction
 nucleoside derivative: DT, drug therapy
 nucleoside derivative: CB, drug combination
 proteinase inhibitor: CB, drug combination
 proteinase inhibitor: DT, drug therapy
 proteinase inhibitor: PD, pharmacology
 riluzole: DT, drug therapy
 riluzole: PD, pharmacology
 ritonavir: DT, drug therapy
 ritonavir: PD, pharmacology
 ritonavir: CB, drug combination
 saquinavir: PD, pharmacology
 saquinavir: CB, drug combination
 saquinavir: DT, drug therapy
 sevoflurane
 sulfonylurea: DT, drug therapy
 sulfonylurea: CB, drug combination
 sumatriptan: DT, drug therapy
 sumatriptan: PD, pharmacology
 sumatriptan succinate
 CAS REGISTRY NO.: (alendronic acid) 66376-36-1; (dexfenfluramine) 3239-44-9,
 3239-45-0; (losartan potassium) 124750-99-8; (acarbose)
 56180-94-0; (biguanide) 56-03-1; (desflurane) 57041-67-5;
 (enoxaparin) **9041-08-1**; (indinavir) 150378-17-9,
 157810-81-6; (metformin) 1115-70-4, 657-24-9;
 (methotrexate) 15475-56-6, 59-05-2, 7413-34-5;
 (misoprostol) 59122-46-2, 59122-48-4; (proteinase
 inhibitor) 37205-61-1; (riluzole) 1744-22-5; (ritonavir)
 155213-67-5; (saquinavir) 127779-20-8; (sevoflurane)
 28523-86-6; (sumatriptan) 103628-46-2; (sumatriptan
 succinate) 103628-48-4
 CHEMICAL NAME: Cozaar; Invirase; Norvir; Crixivan; Glucophage; Precose;
 Fosamax; Redux; Imitrex; Rilutek; Folex; Cytotec; Lovenox;
 Fragmin; Varivax; Havrix; Suprane

L76 ANSWER 35 OF 35 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 ACCESSION NUMBER: 2000-442268 [38] WPIDS
 DOC. NO. CPI: C2000-134436
 TITLE: Use of **low** molecular weight **heparin**
 for treatment and prevention of **motor**
neuron disease, e.g. amyotrophic
lateral sclerosis.
 DERWENT CLASS: B04
 INVENTOR(S): STUTZMANN, J M; UZAN, A; STUTZMANN, J
 PATENT ASSIGNEE(S): (AVET) AVENTIS PHARMA SA; (STUT-I) STUTZMANN J; (UZAN-I)
 UZAN A
 COUNTRY COUNT: 83
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN	IPC
WO 2000035462	A1	20000622	(200038)*	FR	18	A61K031-727	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL							
OA PT SD SE SL SZ TZ UG ZW							
W: AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS							
JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK SL							
TR TT UA US UZ VN YU ZA							
FR 2787329	A1	20000623	(200038)			A61K031-738	
AU 2000015697	A	20000703	(200046)			A61K031-727	
NO 2001002849	A	20010608	(200154)			A61K000-00	
EP 1140119	A1	20011010	(200167)	FR		A61K031-727	

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
US 2002040013 A1 20020404 (200227) A61K031-727
JP 2002532431 W 20021002 (200279) 19 A61K031-727

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000035462	A1	WO 1999-FR3109	19991213
FR 2787329	A1	FR 1998-15919	19981217
AU 2000015697	A	AU 2000-15697	19991213
NO 2001002849	A	WO 1999-FR3109	19991213
		NO 2001-2849	20010608
EP 1140119	A1	EP 1999-958308	19991213
		WO 1999-FR3109	19991213
US 2002040013	A1 Cont of	WO 1999-FR3109	19991213
		US 2001-881267	20010614
JP 2002532431	W	WO 1999-FR3109	19991213
		JP 2000-587782	19991213

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000015697	A Based on	WO 2000035462
EP 1140119	A1 Based on	WO 2000035462
JP 2002532431	W Based on	WO 2000035462

PRIORITY APPLN. INFO: FR 1998-15919 19981217

INT. PATENT CLASSIF.:

MAIN: A61K000-00; A61K031-727; A61K031-738
SECONDARY: A61P009-10; A61P025-00; A61P025-28; A61P043-00
ADDITIONAL: C08B037-10

BASIC ABSTRACT:

WO 200035462 A UPAB: 20000811

NOVELTY - Use of **low** molecular weight **heparin** (I) to produce a medicine that promotes survival and/or growth of motor neurons.

ACTIVITY - Cytoprotective; neurotrophic.

A mixed culture of astrocytes and motor neurons (MN) was treated with the **low** molecular weight **heparin Enoxaparine**

(Ia), then after 2-3 days the number of viable MN assessed from:

(i) immunoreactivity for the homoprotein Islet1/2 or for neurofilaments; and

(ii) presence of neurites longer than 10 cell diameters.

At 10 ng/ml (Ia), the mean number of MN was 196% and the mean MN survival was 120.7%, both relative to a vehicle-only control as 100%. The number of very large MN was 66 per cubic centimeters (cc) in presence of (Ia) compared with 38 per cc in a control.

MECHANISM OF ACTION - None given.

No biological data given.

USE - (I) is specifically used to treat and/or prevent **motor neuron diseases**, particularly amyotrophic lateral sclerosis, progressive spinal muscular atrophy and infantile muscular atrophy.

Dwg.0/0

FILE SEGMENT: CPI

FIELD AVAILABILITY: AB; DCN

MANUAL CODES: CPI: B04-C02E; B14-J01; B14-J05A

FILE 'HOME' ENTERED AT 15:15:41 ON 12 DEC 2003

GS-12 CASE(S) FOR REVIEW 1ST REVIEW

Section 1 - Patent Examining Functions & Applicability

Function	GS-7	GS-9	GS-11	GS-12	GS-13+
1(a). Checking applications for formal matters	Performs after Preliminary Instruction	Performs	Performs	Performs	Performs
1(b). Checking application for technological accuracy	Performs after Preliminary Instruction (Core)	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
2. Treating disclosure statements & statements & claims for priority	Performs after Preliminary Instruction	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
3. Analyzing disclosure & claims for compliance with 35 U.S.C. 112	Performs after Preliminary Instruction	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
4. Planning field of search	Performs after Preliminary Instruction	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
5. Conducting search	Performs after Preliminary Instruction (Core)	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
6. Formulating rejections under 102/103 or determining how claims distinguish over prior art	Performs after Preliminary Instruction	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
7. Determining whether amendment introduces new matter.	Performs	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
8. Determining whether restriction is proper.	Performs	Performs	Performs	Performs	Performs
9. Determining operability/utility.	Performs after Preliminary Instruction	Performs	Performs	Performs	Performs
10. Evaluating/applying case law as necessary.	Performs after Preliminary Instruction	Performs	Performs	Performs	Performs
11. Evaluating sufficiency of affidavits/declarations.	Performs after Preliminary Instruction	Performs (Core)	Performs (Core)	Performs (Core)	Performs (Core)
12. Determining whether appropriate line of patentable distinction maintained between applications &/or patents.	Performs after/Performs after Preliminary Instruction	Performs	Performs	Performs	Performs
13. Includes "Why?" in 103 rejections.	Performs after Preliminary Instruction	Performs	Performs	Performs	Performs
14. Evaluating sufficiency of reissue oath/declaration.	Performs after Preliminary Instruction	Performs	Performs	Performs	Performs